The data are compelling and consistent–non-opioid OMIDRIA makes cataract surgery better for you and your patientsPublished and presented clinical studies and manuscripts report that in post-launch (i.e., not included in current labeling), prospective and retrospective, double-masked and open-label, cohort and case-controlled, single- and multi-center analyses, the use of OMIDRIA, compared to the surgeons’ standard of care, statistically significantly:
- Prevents Intraoperative Floppy Iris Syndrome (IFIS)15
- Reduces complication rates (epinephrine comparator)2
- Decreases use of pupil-expanding devices (epinephrine comparator)2,16-19
- Reduces surgical times (epinephrine comparator)2,16,19
- Prevents miosis during femtosecond laser-assisted surgery (epinephrine comparator)18,20
- Improves uncorrected visual acuity on day after surgery (epinephrine comparator)2
- Delivers NSAID to the anterior chamber and related structures better than routine preoperative topical drug administration, resulting in effectively complete postoperative inhibition of COX-1 and COX-212,21
- Decreases the incidence of CME, rebound iritis, and pain/photophobia when used with a post-op NSAID only (no steroid) compared to post-op steroids +/- NSAIDs (no OMIDRIA)22,23
- Reduces the need for opioids (i.e., fentanyl) during cataract surgery while decreasing pain scores24
Reduces complication rates2
Patients who received OMIDRIA had fewer intraoperative and postoperative complications, including capsular tears, lens decentration, retained lens fragments, macular puckering, and retinal detachment.
Retrospective case review. Co-author E. Donnenfeld is a consultant for Omeros.
Reduces surgical time and pupil-expanding device use19
In the OMIDRIA group, use of pupil-expanding devices (PED) was reduced by 67% and surgical time was reduced by 7.3%.
Retrospective case review, single surgeon, two centers. Omeros Corporation provided support for this study. C. Matossian is a consultant for Omeros.
Reduces use of pupil-expanding devices in high-risk patients and in femtosecond laser surgery16,18
With OMIDRIA, zero patients at risk for intraoperative miosis* required pupil-expanding devices.
- Additionally, mean surgical time with OMIDRIA was significantly shorter compared to epinephrine (10.1 vs 14.3 minutes; p=0.0068) in high-risk patients
Retrospective case review analysis of patients at risk for requiring a pupil-expanding device. Dr Visco is a consultant for Omeros Corporation, which provided financial support for this study.
|*||Patients with presurgical examination of pupil dilation ≤5.0 mm after being administered topical tropicamide 1% and phenylephrine 2.5% or history of IFIS during surgery in the fellow eye.16|
With OMIDRIA, there was an 83% reduction in pupil-expanding device usage in femtosecond laser surgeries.
- Additionally, mean surgical time with OMIDRIA was significantly shorter compared to epinephrine (8.10 vs 9.39 minutes; p=0.007) in femtosecond laser-assisted cataract surgeries
Retrospective case review analysis of patients undergoing femtosecond laser-assisted cataract surgery. Dr Walter is a consultant for Omeros Corporation.
The OMIDRIA group had an 87% overall reduction in observed IFIS symptoms, 79% reduction in iris prolapse, and 90% reduction in severe billowing.
Investigator-initiated, double-masked study in 50 male patients (50 eyes). Dr Silverstein is a consultant for Omeros Corporation.